-, PARACETAMOL , MK-2870, PACLITAXEL , -, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -, CARBOPLATIN , PACLITAXEL ALBUMIN-BOUND, DEXAMETHASONE
MK-2870-023
Phase 3 small_molecule active
Quick answer
-, PARACETAMOL , MK-2870, PACLITAXEL , -, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -, CARBOPLATIN , PACLITAXEL ALBUMIN-BOUND, DEXAMETHASONE for Participants with treatment-naïve metastatic squamous Non-small Cell Lung Cancer (NSCLC) is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Participants with treatment-naïve metastatic squamous Non-small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active